We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Microfluidics Offers Superior Drug Encapsulation
Product News

Microfluidics Offers Superior Drug Encapsulation

Microfluidics Offers Superior Drug Encapsulation
Product News

Microfluidics Offers Superior Drug Encapsulation


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Microfluidics Offers Superior Drug Encapsulation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dolomite Microfluidics is making microencapsulation technology more widely accessible with the Telos® droplet system, designed for high throughput and easy scale up. The modular components provide scientists with excellent process control, and the ability to choose from a range of particle diameters between 10 and 50 µm on a single piece of hardware.

PLGA, or poly(lactic-co-glycolic acid), is a copolymer commonly used for drug microencapsulation. Precise manipulation of particle size, shape and architecture is extremely important to the efficacy of the candidate drug. However, conventional emulsion-based batch methods result in uneven API distribution and particle polydispersity, requiring additional size-selection and leading to low particle yields and significant loss of API. Dolomite’s continuous flow microfluidic method overcomes these obstacles, providing almost 100 percent encapsulation within precisely controlled, monodisperse PLGA particles, in a single reproducible step.

Mark Gilligan, CEO and founder of Dolomite Microfluidics, said: “For over 15 years, we have been developing microfluidic technologies to enable efficient microencapsulation. We understand that uniform API distribution, reproducibility and the ability to scale up are critical in drug delivery applications. With Dolomite technology, microencapsulation has never been easier.”


Advertisement